Business News • PR NewsWire • Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37

Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37

Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37

OSLO, Norway, Nov. 30, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, will today host an R&D day starting at 14:00 CET/ 13:00 GMT/ 08:00 ET. The meeting will be...

View More : https://www.prnewswire.com:443/news-releases/nordic-nanovector-rd-day-building-value-from-betalutin-and-a-pipeline-of-br...

Releted News by prnewswire

Modulaire Group releases third quarter 2021 Financial Report

MPC Energy Solutions publishes Q3 2021 results

E-commerce Packaging Market Driven by the Growth of the E-commerce Sector | 17,000+ Technavio Research Reports